ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma's subsidiary acquired A1 Biochem USA Inc for ₹9.47 Crore. This 100% acquisition expands its contract research and development services capabilities in the USA.
Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Q1FY27 revenue grew 16% YoY to ₹9,150 Cr. EBITDA margin stood at 21% with PAT of ₹1,032 Cr. Focus remains on complex generics, Lannett integration, and biosimilar monetization.
Aurobindo reported strong Q1FY27 performance with revenue up 16.3% YoY to ₹9,150 Cr and PAT up 25.2% to ₹1,032 Cr, driven by US base business volume gains and European expansion.
Aurobindo Pharma Ltd reported revenue from operations of ₹9,150 Cr (+16.3% YoY) and net profit of ₹1,032 Cr (+25.2% YoY) for Q1 FY27.
Aurobindo delivered record performance in FY26 with revenues at ₹33,653cr and 20.4% EBITDA margins. Strategy focuses on specialty injectables, biosimilars expansion, and backward integration via Pen-G/6-APA projects.
Aurobindo Pharma reported Q4FY26 revenue of ₹8,853 Cr (+5.6% YoY) and PAT of ₹921 Cr (+2.0% YoY). The firm focuses on biosimilars expansion via CuraTeQ and biologics CDMO through TheraNym.
Aurobindo Pharma Ltd reported revenue from operations of ₹8,853 Cr (+5.6% YoY) and net profit of ₹920.8 Cr (+2.0% YoY) for Q4 FY26.